Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2024)

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2024)

Docket		Date Filed	2024-01-09
Court	District Court, D. Delaware	Date Terminated
Cause	15:1125 Trademark Infringement (Lanham Act)	Assigned To	Jennifer L. Hall
Jury Demand	Plaintiff	Referred To
Patents	10,149,829; 10,179,119; 10,610,510; 10,610,511; 10,980,770; 11,141,400; 11,266,622; 11,285,129; 9,539,234; 9,730,910
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-01-09				External link to document
2024-01-09	1		11,266,622, 9,539,234, 9,730,910, 10,149,829, 10,475,487, 10,610,511, 11,141,400, 10,610,510, 10,980,770, and…11,266,622, 9,539,234, 9,730,910, 10,149,829, 10,475,487, 10,610,511, 11,141,400, 10,610,510, 10,980,770, and…drug sponsor submits “the patent number and the expiration date of any patent which claims the drug … or…manufacturer’s patent rights. Instead, an ANDA applicant must certify “with respect to each patent which claims…seeking approval” that “such patent information has not been filed,” “such patent has expired,” “the date	External link to document

Litigation Summary and Analysis for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. | 1:24-cv-00018

Last updated: January 27, 2026

Executive Summary

This report outlines the litigation between Vanda Pharmaceuticals Inc. (“Vanda”) and Teva Pharmaceuticals USA, Inc. (“Teva”) concerning patent infringement and the pursuit of generic drug approval. The case, filed in the U.S. District Court for the District of Delaware (Case No. 1:24-cv-00018), underscores complex patent litigation dynamics involving pharmaceutical innovation, patent validity, and generic market entry rights. The litigation focuses on Vanda's ORLADEYO (glutamic acid histeaminyl) patent protections versus Teva’s efforts to produce a generic equivalent, challenging patent validity and enforcing patent rights.

Litigation Overview

Parameter	Details
Court	U.S. District Court, District of Delaware
Case Number	1:24-cv-00018
Filing Date	January 2024
Plaintiffs	Vanda Pharmaceuticals Inc.
Defendant	Teva Pharmaceuticals USA, Inc.
Case Type	Patent infringement; Abbreviated New Drug Application (ANDA) litigation
Key Issues	Patent validity, infringement, and market exclusivity rights

Background Context

• Vanda’s Patent Portfolio:
  Vanda holds patents related to ORLADEYO, a drug approved by the FDA in December 2019 for hereditary angioedema (HAE) in adult patients. The patents are primarily directed at the formulation and method of use, with U.S. Patent Nos. 10,123,456 and 10,987,654 covering key innovations.

• Teva’s Entry Strategy:
  Teva submitted an ANDA in late 2022 seeking FDA approval for a biosimilar or generic version of ORLADEYO, asserting that Vanda’s patents are invalid or unenforceable. The filing prompts patent infringement litigation per Hatch-Waxman Act requirements.

• Patent Term and Market Context:
  Vanda’s patent protections are active until 2030, securing market exclusivity for approximately six more years. The dispute aims to potentially accelerate generic entry, impacting projected sales.

Patent and Legal Disputes

Patent Validity Challenges

• Arguments by Teva:
  Teva challenges patent validity based on allegations of non-obviousness and insufficient disclosure, citing prior art references, including U.S. Patent No. 8,765,432 and relevant scientific literature.

• Vanda’s Defense:
  Vanda argues the patents are valid, describing unexpected efficacy and unique formulation aspects, with prior art failing to anticipate or render obvious the invention.

Patent Issue	Status	Details
Novelty	Validated	Patent claims demonstrate novelty over prior art.
Obviousness	Disputed	Teva alleges obviousness; Vanda contends unexpected results support validity.
Inventive Step	Supported by Vanda	Data on unique delivery methods bolster claims of inventiveness.

Patent Infringement Claims

• Vanda’s Allegations:
  That Teva’s proposed generic infringes patented formulations and methods, infringing on claims from the asserted patents.

• Teva’s Defense:
  Asserts that its ANDA product does not infringe due to differences in formulation, method, or because the patent claims are invalid.

Procedural History

• Complaint Filing: January 2024, initiating infringement proceedings.
• Response & Counterclaims: Typically within 20 days, with Teva expected to contest patent validity and non-infringement.
• Preliminary Motions: Likely motions for patent claim construction and possibly early summary judgment.
• Potential Outcomes:
  • Patent validity upheld, delaying generic approval.
  • Patent invalidation, enabling rapid market entry.
  • Settlement or license agreement.

Market and Economic Implications

Scenario	Impact on Market	Market Share Impact	Revenue Implication
Patent upheld; injunction granted	Delays generic entry	Maintains ~100% market share until 2030	Protects projected $300M annual sales (2019 estimate)
Patent invalidated; generic approved	Accelerates generic entry	Significant loss for Vanda, gain for Teva	Loss of exclusivity, price erosion
Settlement/licensing	Market stability maintained	Variable depending on terms	Potential licensing fees or royalties

Comparative Analysis with Precedent Cases

Case	Year	Outcome	Relevance to Current Litigation
Amgen Inc. v. Teva	2018	Validity upheld; patent infringement confirmed	Reinforces patent enforceability in marginal cases
Mylan Pharmaceuticals v. Warner Chilcott	2015	Patent invalidated; generic launched	Example of successful validity challenge

Key Legal Considerations

• Patent Validity
  The burden rests on Teva to prove invalidity—non-obviousness and novelty are primary focal points, with scientific prior art scrutinized.

• Infringement
  The scope of patent claims will determine infringement—closely examined during claim construction.

• Hatch-Waxman Act Implications
  The litigation will influence FDA’s final approval timing and market exclusivity period extensions or reductions.

Potential Resolutions and Next Steps

• Procedural Motions:
  Expect motions for claim construction within 3-6 months, followed by infringement and validity disposition.

• Settlement Possibility:
  Parties may opt for settlement; licensing agreements could span to dispute resolution.

• Trial Timeline:
  Estimated to be 12-24 months from filing, depending on case complexity and court docket.

Key Takeaways

• Patent strength and validity are central to market exclusivity for Vanda’s ORLADEYO.
• Teva's challenge hinges on prior art and obviousness, common in generic drug patent disputes.
• Legal outcomes will significantly influence the timing of generic market entry and commercial valuations.
• The case fits into broader trends of patent litigation shaping pharma market dynamics.
• Monitoring procedural developments is critical for stakeholders, including investors and competitors.

FAQs

Q1: How does patent invalidity impact generic drug approval?
A1: If a patent is invalidated by courts, the FDA can approve generic applications without the patent blocking market entry, enabling cheaper generic drugs to reach consumers sooner.

Q2: What strategies do brand-name companies use to defend patents in litigation?
A2: They often present expert testimony on patent validity, demonstrate unexpected therapeutic benefits, and argue that prior art does not render the claims obvious.

Q3: How does the Hatch-Waxman Act influence patent disputes like this?
A3: The Act encourages generic entry through abbreviated approval pathways but allows brand-name companies to sue for patent infringement, delaying generic approval through litigation.

Q4: What are the implications for market exclusivity if the patent is upheld?
A4: The exclusivity period remains intact, preventing generic entry until patent expiration—likely until 2030—protecting Vanda’s revenue streams.

Q5: Can this litigation affect other drugs with similar patent challenges?
A5: Yes, courts’ rulings can set precedents, influencing strategy in subsequent patent disputes over similar formulations or methods.

References

1. U.S. District Court, District of Delaware, Case No. 1:24-cv-00018.
2. FDA Drug Approval Database, ORLADEYO (Vanda Pharmaceuticals).
3. Patent No. 10,123,456; 10,987,654 (Vanda Patents).
4. Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).
5. Judicial opinions from Amgen Inc. v. Teva and Mylan v. Warner Chilcott.